TY - JOUR
T1 - The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma
T2 - Reduced relapse risk in female to male transplants
AU - Gahrton, Gosta
AU - Iacobelli, S.
AU - Apperley, J.
AU - Bandini, G.
AU - Björkstrand, B.
AU - Bladé, J.
AU - Boiron, J. M.
AU - Cavo, M.
AU - Cornelissen, J.
AU - Corradini, P.
AU - Kröger, N.
AU - Ljungman, P.
AU - Michallet, M.
AU - Russell, N. H.
AU - Samson, D.
AU - Schattenberg, A.
AU - Sirohi, B.
AU - Verdonck, L. F.
AU - Volin, L.
AU - Zander, A.
AU - Niederwieser, D.
PY - 2005/3
Y1 - 2005/3
N2 - The impact of the donor gender on outcome in HLA-identical sibling donor hematopoietic stem cell transplantation for multiple myeloma was studied in a retrospective registry study of 1312 patients (476 male to male (M → M); 334 female to male (F → M); 258 male to female (M → F); 244 female to female (F → F) reported to the European Group for Blood and Marrow Transplantation (EBMT). The best overall survival (OS) from the time of transplantation was found in F → F (median 41 months) with no significant difference between other groups (median 25 months in M → M, 18 months in F → M, 19 months in M → F) despite a significantly higher nonrelapse mortality in F → M. This was due to a significantly lower relapse rate (REL) in F → M compared to all other groups. Before 1994, OS was poorer in F → M than in M → M, which improved to similarity from 1994 onwards (median 29 months in M → M and 25 months in F → M). The reduced REL contributed to this improvement in F → M indicting a gender-specific graft vs myeloma effect. Therefore, a female donor is as good as a male one for male patients, while for female patients gender disparity is a negative factor for outcome.
AB - The impact of the donor gender on outcome in HLA-identical sibling donor hematopoietic stem cell transplantation for multiple myeloma was studied in a retrospective registry study of 1312 patients (476 male to male (M → M); 334 female to male (F → M); 258 male to female (M → F); 244 female to female (F → F) reported to the European Group for Blood and Marrow Transplantation (EBMT). The best overall survival (OS) from the time of transplantation was found in F → F (median 41 months) with no significant difference between other groups (median 25 months in M → M, 18 months in F → M, 19 months in M → F) despite a significantly higher nonrelapse mortality in F → M. This was due to a significantly lower relapse rate (REL) in F → M compared to all other groups. Before 1994, OS was poorer in F → M than in M → M, which improved to similarity from 1994 onwards (median 29 months in M → M and 25 months in F → M). The reduced REL contributed to this improvement in F → M indicting a gender-specific graft vs myeloma effect. Therefore, a female donor is as good as a male one for male patients, while for female patients gender disparity is a negative factor for outcome.
KW - Allogeneic stem cell transplantation
KW - Multiple myeloma
UR - http://www.scopus.com/inward/record.url?scp=20144389643&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=20144389643&partnerID=8YFLogxK
U2 - 10.1038/sj.bmt.1704861
DO - 10.1038/sj.bmt.1704861
M3 - Article
C2 - 15696179
AN - SCOPUS:20144389643
VL - 35
SP - 609
EP - 617
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
IS - 6
ER -